Arkema is engaged in the global chemical industry which is a processing industry based on the transformation in one or several stages of raw materials (oil derivatives, gas, minerals, natural products) into more or less complex chemical products, or into plastics obtained by polymerization. In addition, Co. manufactures a wide range of products for other major industries: construction, packaging, chemicals, automotive, electronics, food manufacturing, pharmaceuticals, etc. Co. operates in this industrial context with a business portfolio focused on three segments: High Performance Materials, Industrial Specialties, and Coating Solutions.
  • TickerAKE
  • ISINFR0010313833
  • ExchangeEuronext Paris
  • SectorChemicals
  • CountryFrance

Analysts

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Jean Sassus
  • Jerôme Bodin
  • Léopold Authié
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Veysel Taze
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/12/2018

...

Emmanuel Matot ...
  • Jean-François Granjon

ODDO BHF Small & MIDCAP MORNING NEWS - 11/12/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Jean Sassus
  • Jerôme Bodin
  • Léopold Authié
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Veysel Taze
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/11/2018

...

Emmanuel Matot ...
  • Jean-François Granjon

ODDO BHF Small & MIDCAP MORNING NEWS - 12/11/2018

...

Emmanuel Matot

Solvay : Slightly slower momentum in Q3 for Arkema/Solvay – downward revisions to our target prices

>Arkema is sticking to its cautious EBITDA guidance for this year and has made an opportunistic acquisition - Arkema last Tuesday turned in a satisfactory set of Q3 results, with EBITDA continuing to grow (+5% at € 374m vs consensus = € 371m) although the momentum is slowing (H1 = +8%), with increasingly challenging comps (delivering growth since early 2015).Industrial specialities continue to drive performances at the group (particularly fluorogases, thiochemica...

Arkema - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Arkema - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Arkema - September 2017 (LTM): Peer Snapshot

Peer Snapshot:  Arkema - September 2017 (LTM) 20 December 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17

Arkema: Update to Discussion of Key Credit Factors

CORPORATES CREDIT OPINION 5 December 2017 Update RATINGS Arkema Domicile France Long Term Rating Baa2 Type LT Issuer Rating - Dom Curr Outlook Stable Please see the  ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Francois Lauras 44-20-7772-5397

Arkema - March 2017 (LTM): Peer Snapshot

Peer Snapshot:  Arkema - March 2017 (LTM) 23 June 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Mar-17 FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM Dec-16

Emmanuel Matot

Solvay : Slightly slower momentum in Q3 for Arkema/Solvay – downward revisions to our target prices

>Arkema is sticking to its cautious EBITDA guidance for this year and has made an opportunistic acquisition - Arkema last Tuesday turned in a satisfactory set of Q3 results, with EBITDA continuing to grow (+5% at € 374m vs consensus = € 371m) although the momentum is slowing (H1 = +8%), with increasingly challenging comps (delivering growth since early 2015).Industrial specialities continue to drive performances at the group (particularly fluorogases, thiochemica...

Emmanuel Matot

Solvay : Léger ralentissement de la dynamique au T3 pour Arkema/Solvay – Abaissement de nos objectifs de cours

>Arkema maintient sa guidance prudente d’Ebitda pour cette année et réalise une acquisition opportuniste - Arkema a publié mardi dernier des résultats T3 satisfaisants, l’Ebitda s’inscrivant toujours en progression (+5% à 374 M€ vs consensus = 371 M€) même si la dynamique ralentit (S1 = +8%) avec des bases de comparaison de plus en plus challenging (croissance au rendez-vous depuis début 2015).Les Spécialités industrielles continuent de tirer les performances du ...

Rob Hales

Morningstar | First Signs of PMMA Normalization For Arkema in 4Q; Shares Fairly Valued

No-moat Arkema reported third-quarter results that were in line with consensus and our expectations. EBITDA of EUR 374 million was up 5% over 2017. Guidance for a mid-single-digit increase in EBITDA for 2018 was confirmed, in line with our forecast. Like other chemical companies that have already reported this quarter, Arkema noted a changing macroeconomic environment and continued raw material inflation. We think the most important item in the quarter was Arkema's report of a slight normalization in polymethyl methacrylate, or PMMA, at the end of the quarter. The PMMA market has remained tig...

Rob Hales

First Signs of PMMA Normalization For Arkema in 4Q; Shares Fairly Valued

No-moat Arkema reported third-quarter results that were in line with consensus and our expectations. EBITDA of EUR 374 million was up 5% over 2017. Guidance for a mid-single-digit increase in EBITDA for 2018 was confirmed, in line with our forecast. Like other chemical companies that have already reported this quarter, Arkema noted a changing macroeconomic environment and continued raw material inflation. We think the most important item in the quarter was Arkema's report of a slight normalizati...

Alexandre Iatrides ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • François Maury
  • Georges Dieng
  • Philippe Ourpatian
  • Stephane Houri
  • Veysel Taze

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/06/2018

...

2 directors sold after exercising options/sold

Two Directors at Arkema sold after exercising options/sold 21,300 shares at between 107.950EUR and 109.450EUR. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is re...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Jean Sassus
  • Jerôme Bodin
  • Léopold Authié
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Veysel Taze
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/12/2018

...

Emmanuel Matot ...
  • Jean-François Granjon

ODDO BHF Small & MIDCAP MORNING NEWS - 11/12/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Jean Sassus
  • Jerôme Bodin
  • Léopold Authié
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Veysel Taze
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/11/2018

...

Emmanuel Matot ...
  • Jean-François Granjon

ODDO BHF Small & MIDCAP MORNING NEWS - 12/11/2018

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 11/06/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 18/05/2018

The remuneration awarded to Thierry Le Hénaff, Chairman & CEO, was excessive in 2017. He received € 4.5 M and may receive the same amount next year. Moreover the long term years of this directors, François Enaud and Thierry Morin, reduce the independent rate of the board of directors.

Jehanne Leroy

Proxy Report - 18/05/2018

Cette année, Proxinvest attire de nouveau l'attention des actionnaires sur la rémunération attribuée et la rémunération attribuable à M. Le Hénaff qui paraissent excessive. Ainsi en 2017, le Président Directeur Général a perçu un peu plus de 4,5 M d'euros; et pourrait se voir attribuer pas moins de la même somme en 2018. Ces rémunérations excessives sont étonnantes, surtout pour une entreprise étant membre du SBF 120. Le conseil comprendra avec un nouvel administrateur. Cependant deux administrateurs seront requalifiés à raison de leurs anciennetés dans la société. De ce fait, le taux d'indép...

Jérôme VINERIER

Short term view - ARKEMA : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €87.81. The background trend would be questioned should prices rise above €99.54.

Jérôme VINERIER

Analyse court terme - ARKEMA : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 87,81 €. La tendance de fond serait remise en cause en cas de franchissement de 99,54 €.

Jérôme VINERIER

Analyse court terme - ARKEMA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 87,81 €, puis 84,28 €. Le franchissement de 99,54 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - ARKEMA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €87.81, then €84.28. Passing €99.54 would question the continuation of the fall.

Jérôme VINERIER

Medium term view - ARKEMA : The trend is uncertain.

The trend is uncertain. Prices are falling and they may accelerate to the downside. A new bearish trend is attempting to emerge.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch